Big deal for Bionomics
Friday, 20 June, 2008
Adelaide-based biotech Bionomics (ASX: BNO) has signed a significant development and licensing agreement with Merck Serono, which will see the German pharmaceutical manufacturer develop new treatments for multiple sclerosis and other autoimmune conditions based on Bionomics compounds.
The agreement may be worth up to US$47 million if successful. The company will also be eligible to received undisclosed royalties on the net sales of licensed products.
Bionomics' proprietary Kv1.3 compounds inhibit the production of cells which cause nerve damage in patients suffering from MS and related nerve disorders.
Under the terms of the agreement, Bionomics will receive an upfront payment of $2 million for continued research funding, and Merck Serono will pay clinical development costs.
Bionomics' Kvl.3 compounds target the potassium ion channel Kvl.3, a key modulator of the immune system. The company also has a vascular disruption agent in clinical trials for cancer and is researching GABA-A agonists for epilepsy.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
